Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by Kswdeluxon Dec 05, 2022 3:52pm
331 Views
Post# 35151837

Hostile Take-Over ???

Hostile Take-Over ???

In order for someone to attempt a hostile take over, they would have to buy up at least 10% of the float to even begin to push the issue. More likely 15-20% to be successful.

At the daily volumes we are experiencing at this time it would take well over a month to buy up that much stock and accumulating a minimum of 10% of the float and would significantly drive up the stock price.

if they were a corporation, that corporation would have to disclose to its share holders within 28 days that they were buying ONC. So their buying would be exposed within 28 day. 


If they needed more that 10%, they become a majot share holder  once they own more than 10%, and then have to report all buying and selling, until they ar3 less than 10% again.

If they did manage to collect 10% or more and tried to push the issue, ONC would go to the SEC and request a 3rd party fair market evaluation of ONC and that information would then be published to ONC shareholders, and as of that NR the new trading share priceewould jump to the determined 3rd party market evaluation.

That 3rd party evaluation will be in depth and take into consideration both registration studies, fast track designation, IND and CAR T, etc... and the value of revenues after such approvals.

Nobody is forcing a hostile take over at $3 a share. 

Based on all of that... IMHO any offer will only come from BP, and involved BP, as only they, at this time, know the finite unknown detail to make an appropriate offer.

All good... I still favour Roche for that...

but not worried about a hostile take over...

Cheers everyone!

I ammvery curious as to what we will see on Dec 7th..... coming fast....

<< Previous
Bullboard Posts
Next >>